Envoy Medical, Inc.
No SEC Form 4 filings for $COCH in the last 30 days.
See all $COCH insider activity →Lake Street initiated coverage on Envoy Medical (COCH) with a buy rating and $2.50 price target, citing potential upside of 270%. The company's Acclaim cochlear implant is in development, with pivotal trial data meeting expectations. Envoy reported Q2 2026 revenue of $51,000 and a net loss of $7.3 million. Other analysts maintain buy ratings with varying price targets.
Envoy Medical, Inc. (COCH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers On August 24, 2026, Envoy Medical, Inc. (the “Company”) appointed Robert Potashnick to serve as the Company’s Chief Accounting Officer and Vice President of Finance. M
Analysts updated price targets for several companies. Baird raised Ross Stores (ROST) target to $270, Parsons (PSN) to $57, and Deere (DE) to $640. BTIG cut Walmart (WMT) target to $140. HSBC raised Ternium (TX) target to $55. Rothschild & Co increased Equifax (EFX) target to $235. Other changes include Envoy Medical (COCH), MDxHealth (MDXH), Hometrust Bancshares (HTB), and Haemonetics (HAE).
Over the past 7 days, AlphAI's AI scored 1 news story mentioning COCH (Envoy Medical, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent COCH coverage spans corporate actions, earnings and financial news.
Analyst initiation and upgraded price target suggest upside potential.
New executive hire with compensation details may affect investor perception of management stability and cost structure.
Target cut indicates downside risk.
Regulatory and clinical progress increases the probability of eventual PMA acceptance and de-risks the timeline toward a 2027 final module submission.
Clinical-trial execution milestone reduces near-term execution risk and supports the company’s stated path to PMA submission, but it is not yet regulatory approval.
AlphAI scores every news story that mentions COCH with an AI model for sentiment and relevance, and aggregates insider trades from Envoy Medical, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Lake Street initiated coverage on Envoy Medical (COCH) with a buy rating and $2.50 price target, citing potential upside of 270%. The company's Acclaim cochlear implant is in development, with pivotal trial data meeting expectations. Envoy reported Q2 2026 revenue of $51,000 and a net loss of $7.3 million. Other analysts maintain buy ratings with varying price targets.
2 min readEnvoy Medical, Inc. (COCH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers On August 24, 2026, Envoy Medical, Inc. (the “Company”) appointed Robert Potashnick to serve as the Company’s Chief Accounting Officer and Vice President of Finance. M
1 min readAnalysts updated price targets for several companies. Baird raised Ross Stores (ROST) target to $270, Parsons (PSN) to $57, and Deere (DE) to $640. BTIG cut Walmart (WMT) target to $140. HSBC raised Ternium (TX) target to $55. Rothschild & Co increased Equifax (EFX) target to $235. Other changes include Envoy Medical (COCH), MDxHealth (MDXH), Hometrust Bancshares (HTB), and Haemonetics (HAE).
2 min readEnvoy Medical, Inc. (COCH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Envoy Medical Reports Second Quarter 2026 Results and Achieves Key Regulatory and Clinical Milestones Submitted First Module of Modular PMA Application to FDA Subsequent to Quarter End, the Company Reported Positive 12-Month Stage 1 Data Showing Continued Improvement
6 min readEnvoy Medical (NASDAQ: COCH) said it has passed the three-month visit milestone for all 56 patients in its pivotal trial of the investigational fully implanted Acclaim cochlear implant. The company continues collecting safety and study measures for a planned FDA PMA submission. It expects six-month enrollment by late 2026 and 12-month study data by April 2027.
2 min readEnvoy Medical (NASDAQ: COCH) reported positive 12-month interim results from Stage 1 of its pivotal trial for the investigational fully implanted Acclaim cochlear implant. In 10 participants, mean CNC word recognition rose to 53.2% from a 15.2% baseline. No protocol-defined serious adverse events were reported. Stage 2 is fully enrolled.
4 min readCochin Shipyard shares fell 4.1% to ₹1,445.1 on Tuesday after India’s government announced an Offer for Sale of up to 5.04% of its stake at a floor price of ₹1,400, a >7% discount to the prior day. The OFS supply weighed on the stock; government holds 67.92%.
3 min readIndia’s Department of Investment and Public Asset Management said the government will sell up to 5.04% of its stake in Cochin Shipyard via an offer for sale. The base sale is 2.52% with an option for another 2.52% if oversubscribed. The floor price is 1,400 rupees/share, a >7% discount to the last close. Non-retail opens Tuesday; retail Wednesday.
2 min readEnvoy Medical, Inc. (COCH) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. false 0001840877 0001840877 2026-06-24 2026-06-24 0001840877 COCH:ClassCommonStockParValue0.0001PerShareMember 2026-06-24 2026-06-24 0001840877 COCH:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceOf11.50PerShareMember 2026-06-24 2026-06-2
2 min readA lock-up agreement applies to 28,934,960 Class A Common Stock of Envoy Medical, Inc., starting from February 12, 2026, and ending on April 13, 2026. This agreement restricts executive officers and directors from selling or offering these shares for 60 days following the offering's closing, with customary exceptions for existing stock option plans.
2 min read